CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Vehicle (Placebo) applied BID +2 moredrug
Likely dose
QRX-101 75 mcg/g ointment applied QDfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00373516
NCT00373516Phase 2Completed
CompareCT.gov

A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Study of the Safety and Efficacy of Two Dosing Regimens of QRX-101 (Becocalcidiol) Ointment in the Treatment of Plaque-Type Psoriasis

QuatRx Pharmaceuticals Company·interventional·Posted Sep 8, 2006·Updated Sep 8, 2006

In Brief

A Phase 2 clinical trial evaluating Vehicle (Placebo) applied BID, QRX-101 75 mcg/g ointment applied QD, and 1 other intervention for Psoriasis. Completed, across 12 sites.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of two dosing regimens of QRX-101 ointment (75 mcg/g QD and 75mcg/g BID) in the treatment of plaque-type psoriasis when applied topically twice daily for 8 weeks

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 8, 2006
Enrollment StartSep 1, 2004
Study CompletionMar 1, 2005
TodayJul 2, 2026
Posted 19.8 years ago

Interventions

Vehicle (Placebo) applied BIDdrug

QRX-101 75 mcg/g ointment applied QDdrug

QRX-101 75 mcg/g ointment applied BIDdrug